RxDoctor Payments Data

William Zeiger, MD

Neurology · Los Angeles, CANPI 1154769933

Payments from drug & device makers

$43,930in general payments, 2019–2025

Across 8 payments — averaging $5491.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$44K
  • Boston Scientific$84
  • AbbVie$26
  • Neurocrine Biosciences, Inc.$25
  • Amneal Pharmaceuticals LLC$23
  • Acadia Pharmaceuticals Inc$21

What the payments were for

  • Grants$43,750100%
  • Food & beverage$950%
  • Education$840%

General payments by program year

19
20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$43,930 in reported general payments places this provider in the 85th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$39,635
Medicare patients
91
Services billed
372

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate28$171,468
RytaryCarbidopa/Levodopa40$65,241
AustedoDeutetrabenazine13$62,184
NeuproRotigotine12$9,951
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone11$9,494
Carbidopa14$8,617
Rasagiline Mesylate30$6,166
Carbidopa-Levodopa ErCarbidopa/Levodopa53$4,216
Duloxetine Hcl16$3,583
Carbidopa-LevodopaCarbidopa/Levodopa76$2,352
Modafinil12$2,273
Escitalopram Oxalate23$390
Clonazepam13$339
Gabapentin22$311
Donepezil Hcl25$306

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$21$171,46828 claims
Amneal Pharmaceuticals LLCRytary$23$65,24140 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,996 neurology providers in California.

Other neurology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →